Ascentage Pharma Group International (AAPG) Enterprise Value (2022 - 2025)
Ascentage Pharma Group International (AAPG) has disclosed Enterprise Value for 4 consecutive years, with -$168.6 million as the latest value for Q4 2025.
- For Q4 2025, Enterprise Value fell 35.6% year-over-year to -$168.6 million; the TTM value through Dec 2025 reached -$168.6 million, down 35.6%, while the annual FY2025 figure was -$166.4 million, 30.29% down from the prior year.
- Enterprise Value hit -$168.6 million in Q4 2025 for Ascentage Pharma Group International, down from -$124.3 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$124.3 million in Q4 2024 and bottomed at -$189.2 million in Q4 2022.
- Average Enterprise Value over 4 years is -$156.6 million, with a median of -$156.4 million recorded in 2025.
- Year-over-year, Enterprise Value increased 23.8% in 2023 and then crashed 35.6% in 2025.
- Ascentage Pharma Group International's Enterprise Value stood at -$189.2 million in 2022, then increased by 23.8% to -$144.2 million in 2023, then grew by 13.76% to -$124.3 million in 2024, then plummeted by 35.6% to -$168.6 million in 2025.
- According to Business Quant data, Enterprise Value over the past three periods came in at -$168.6 million, -$124.3 million, and -$144.2 million for Q4 2025, Q4 2024, and Q4 2023 respectively.